Trial reportClinical rheumatology2025
Is there an additional benefit of ultrasound-guided coracohumeral ligament hydrorelease in cases with primary adhesive capsulitis undergoing ultrasound-guided shoulder hydrodilatation?
Trial report in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary adhesive capsulitis (AC) of the shoulder is a chronic, painful condition characterized by progressive restriction of shoulder range of motion. While conservative management remains the first-line treatment, its efficacy is sometimes limited, prompting exploration of adjunctive interventions. Recent studies have highlighted the effectiveness of hydrorelease of the coracohumeral ligament (CHL) in improving shoulder mobility. This study aimed to evaluate whether ultrasound-guided hydrorelease of the CHL confers additional clinical benefit in patients with shoulder AC undergoing ultrasound-guided hydrodilatation.
methodsPatients diagnosed with primary AC were randomly assigned to one of two groups. Group 1 received both ultrasound-guided hydrodilatation and CHL hydrorelease, while Group 2 received ultrasound-guided hydrodilatation alone. Clinical evaluations were conducted at baseline, immediately post-injection, and at 1 week, 1 month, and 3 months post-injection. Outcome measures included the Visual Analog Scale (VAS) for pain, shoulder range of motion (ROM) (including flexion, abduction, internal rotation, and external rotation), and the Shoulder Disability Index (SDI).
resultsBoth groups demonstrated significant improvements from baseline in pain intensity, shoulder ROM and SDI scores at all follow-up time points. However, no statistically significant differences were observed between the two groups regarding the magnitude of improvement in any of the evaluated parameters.
conclusionUltrasound-guided hydrodilatation is effective in reducing pain, improving shoulder range of motion and function in patients with primary AC. However, the addition of CHL hydrorelease does not appear to provide further benefit in terms of pain relief, range of motion, or functional outcomes. Key Points •Ultrasound-guided hydrodilatation therapy is an effective treatment choice for primary adhesive capsulitis of the shoulder. •Patients receiving hydrodilatation treatment do not benefit further from applying hydrorelease to the coracohumeral ligament.
Indexed as
Identifiers
40965721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.